Generics Attract Royalty Funding Options Too
Executive Summary
Generics firms also have more financing options, it seems. Last month, Paul Capital Partners, through its Paul Royalty Fund, agreed to invest $27 million in the development of 16 dermatology products at India's Glenmark Pharmaceuticals. It's not big money, but the deal points to the growing clout of the generic segment of the pharma industry.
You may also be interested in...
No Dilution Necessary: The Promise of Project Financing
Project financing, claim its proponents-in particular Symphony Capital-offers an alternative to highly dilutive equity offerings, preserving the upside from the development of a successful product for the biotech. That's true, though this expensive capital isn't for everyone. Yet as Big Pharma's productivity challenge deepens, project financing is helping to swing the balance of power further towards small companies.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.